Hypothesis

Aging hallmarks arise from a self-sustaining oscillator that links vascular nitric oxide (NO) signaling, epigenetic NAD+-dependent chromatin regulation, and mitochondrial redox state. This Vascular-Epigenetic Metabolic Oscillator (VEMO) does not act as a single master gene but as a coupled feedback loop that propagates dysfunction across tissues, explaining why interventions targeting any single node improve multiple hallmarks without fully reversing aging.

Mechanistic Basis

• Declining NO bioavailability in the endothelium reduces cGMP-PKG signaling, leading to reduced SIRT1 activation and lower NAD+ consumption. This shifts the NAD+/NADH ratio toward a more reduced state, inhibiting SIRT3-mediated mitochondrial deacetylation and increasing ROS production.
• Elevated mitochondrial ROS oxidizes Tet enzymes, impairing 5-hmC formation and causing focal loss of repressive H3K27me3 marks at promoters of glycolytic and antioxidant genes, mirroring the Drosophila H3K27me3-metabolism link [elifesciences.org/articles/35368].
• The resulting epigenetic drift diminishes expression of endothelial NO synthase (eNOS) and antioxidant enzymes, further lowering NO and completing the loop.
• Because NO diffuses systemically, oscillations in vascular tone transmit metabolic stress to distant organs, organ-specific chromatin landscapes then determine which hallmarks (e.g., proteostasis failure in brain, senescence in skin) manifest first, accounting for asynchronous aging observed in heterochronic parabiosis studies [doi.org/10.1007/s11357-020-00180-6].

Testable Predictions

1. Pharmacological enhancement of NO signaling (e.g., with nitrite or PDE5 inhibitors) will restore NAD+/NADH balance, increase SIRT1/SIRT3 activity, and reestablish H3K27me3 levels in vascular endothelium of aged mice.
2. Tissue-specific CRISPR-dCas9-TET1 targeting of the eNOS promoter in aged animals will dampen the oscillator, reducing mitochondrial ROS and improving multiple hallmarks (e.g., lower p16^INK4a^ senescence, improved proteasome activity) even without changing chronological age.
3. Disrupting the oscillator by overexpressing mitochondrial SOD2 will break the ROS-epigenetic arm, lowering vascular stiffness and extending lifespan, whereas overexpressing a nuclear-locked SIRT1 mutant will have a weaker effect, confirming the primacy of the vascular-initiated loop.

Experimental Approach

• Use aged C57BL/6 mice treated with oral nitrite (100 mM in drinking water) for 8 weeks; measure plasma NOx, aortic cGMP, cardiac NAD+/NADH, endothelial SIRT1 activity, aortic H3K27me3 ChIP-seq, and circulating senescence markers.
• Parallel groups receive endothelial-specific dCas9-TET1 via AAV9; assess the same endpoints plus tissue-specific transcriptomics.
• Include control groups with mitochondrial SOD2 overexpression via AAV9 and nuclear-targeted SIRT1 overexpression.
• Perform longitudinal MRI for arterial stiffness, grip strength, and cognitive testing to capture functional hallmarks.

Falsifiability

If NO restoration fails to alter NAD+/NADH ratios, SIRT activity, or H3K27me3 patterns, or if epigenetic editing of eNOS does not dampen downstream mitochondrial ROS and hallmarks, the VEMO model would be falsified. Likewise, if mitochondrial antioxidant overexpression rescues vascular function without affecting epigenetic marks, the proposed vascular-initiated direction would be unsupported.

Implications

Targeting the oscillator's phase—rather than individual hallmarks—could yield combinatorial therapies that synchronize vascular, epigenetic, and metabolic states, offering a more coherent strategy to delay multimorbidity.